GANX - CIK 0001819411
Gain Therapeutics, Inc. (GANX) reported net income of -$20.16M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$20.16M | +1.2% |
| FY 2024 | -$20.41M | +8.3% |
| FY 2023 | -$22.27M | -26.6% |
| FY 2022 | -$17.59M | -26.6% |
| FY 2021 | -$13.89M | -288.3% |
| FY 2020 | -$3.58M | - |
Gain Therapeutics, Inc. (GANX) reported net income of -$20.16M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Gain Therapeutics, Inc.'s net income declined from -$3.58M to -$20.16M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.